Loading company
$320.98+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Past performance
- 1W
- +0.6%
- 1M
- +0.3%
- 3M
- -1.8%
- 6M
- -0.6%
- 1Y
- +14.6%
- 5Y
- +21.3%
$320.98+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Just reported
From Penumbra Inc's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$410.1M
+16% y/y
+5.2% q/q
Guided
—
No guide given
Actual
$1.07
-8.5% y/y
+22% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $410.1M | $354.7M | +15.64% |
| Profit | $42.3M | $45.9M | -7.79% |
| Profit per share | $1.07 | $1.17 | -8.55% |
| Free Cash Flow | $26.4M | $42M | -37.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Penumbra Inc has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Penumbra Inc’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$50.7M
+3.9% y/y
+24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.